Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer A G Ord (OP:BAYZF)

57.44 +0.94 (+1.66%)
Streaming Delayed Price Updated: 3:20 PM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bayer A G Ord

< Previous 1 2 3 4 5 Next >
News headline image
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
From Bayer
Via Business Wire
News headline image
U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
From Bayer
Via Business Wire
News headline image
BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION
From Bayer
Via Business Wire
News headline image
Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026
From Bayer
Via Business Wire
News headline image
Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026
From Bayer
Via Business Wire
News headline image
One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin
From Bayer
Via Business Wire
News headline image
New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters
From Bayer
Via Business Wire
News headline image
Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials
From Bayer
Via Business Wire
News headline image
Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farming
From Bayer
Via Business Wire
News headline image
The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical Trials
From Bayer
Via Business Wire
News headline image
Luke Bryan and One A Day® Launch Limited Edition Multivitamin Bottles Available Only at Walmart
From Bayer
Via Business Wire
News headline image
Bayer Group to Consolidate U.S. Glyphosate Business Into Distinct Entity Operating as Ruveon
From Bayer
Via Business Wire
News headline image
Bayer and Iambic Collaborate to Advance Drug Discovery with AI
From Bayer
Via Business Wire
News headline image
Bayer Completes Acquisition of Perfuse Therapeutics
From Bayer
Via Business Wire
News headline image
Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief
From Bayer
Via Business Wire
News headline image
Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions
From Bayer
Via Business Wire
News headline image
Dr. Jost Reinhard Appointed President of Bayer’s Radiology Business
From Bayer
Via Business Wire
News headline image
Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth
From Bayer
Via Business Wire
News headline image
Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease
From Bayer
Via Business Wire
News headline image
Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026
From Bayer
Via Business Wire
News headline image
ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
From Bayer
Via Business Wire
News headline image
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
From Bayer
Via Business Wire
News headline image
Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
From Bayer
Via Business Wire
News headline image
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
From Bayer
Via Business Wire
News headline image
U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer
From Bayer
Via Business Wire
News headline image
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
From Bayer
Via Business Wire
News headline image
Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement
From Bayer
Via Business Wire
News headline image
Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities
From Bayer
Via Business Wire
News headline image
Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis
From Bayer
Via Business Wire
News headline image
Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
From Bayer
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.